The World Health Organization (WHO) anticipates releasing updated guidance on oral pre-exposure prophylaxis (PrEP), containing tenofovir (TDF), as an additional HIV prevention choice. The new guidance is likely to be significantly broader than previously and creates real opportunities to move forward with implementing PrEP as part of comprehensive HIV programmes. This publication, produced collaboratively between UNAIDS, WHO and AVAC, is intended to complement WHO recommendations and support the optimal use of oral PrEP to protect individuals and contribute to ending the AIDS epidemic.
